New Injectable Device Developed for Non-Surgical Nerve Control and Pain Relief

Researchers at NYU Abu Dhabi and Cleveland Clinic Abu Dhabi developed an injectable device to control nerves without surgery, according to reports published June 14, 2026. The technology aims to provide a non-invasive method for pain relief by targeting nerve activity through a delivery system that does not require traditional surgical incisions.

The project combines the academic research capabilities of NYU Abu Dhabi with the clinical expertise of Cleveland Clinic Abu Dhabi. According to Bioengineer.org, the collaboration resulted in a device that can be injected to modulate nerve signals, offering a potential alternative to invasive procedures for patients suffering from chronic pain.

How does the injectable nerve device work?

The device functions as a non-surgical interface for nerve control. While traditional nerve modulation often requires the surgical implantation of electrodes or the physical decompression of nerves, this method uses an injectable delivery system. According to Medical Xpress, the device is designed to control nerves without the need for open surgery, reducing the risk of infection and shortening recovery times for patients.

By bypassing the need for a surgical theater, the researchers aim to make nerve modulation more accessible. The device targets specific nerve pathways to block or alter pain signals before they reach the brain, a process that usually requires more invasive interventions in current medical standards.

Why is this different from current pain relief methods?

Current standards for severe chronic pain often involve systemic medications, which can have widespread side effects, or surgical implants like spinal cord stimulators. The Abu Dhabi partnership’s approach differs by utilizing an injectable format. The National reports that this method plant[s] seed of new pain relief method by shifting the intervention from a surgical procedure to an injectable one.

This shift represents a move toward minimally invasive bioengineering. Unlike chemical nerve blocks, which are often temporary and wear off as the medication is absorbed, a device-based injectable approach potentially offers more precise and sustained control over nerve activity.

What is the role of the Abu Dhabi medical partnership?

The development relied on a cross-sector partnership between a research university and a specialized medical center. NYU Abu Dhabi provided the engineering and theoretical framework, while Cleveland Clinic Abu Dhabi provided the clinical context and patient-care insights necessary to ensure the device meets medical requirements.

This collaboration allows the technology to move more quickly from a laboratory concept to a clinical application. According to Bioengineer.org, the joint effort focuses specifically on non-surgical nerve control, signaling a strategic focus on bioengineering within the UAE’s medical infrastructure.

What happens next for the technology?

The researchers are now focusing on the efficacy and safety of the injectable device. Because the method is described as planting a seed for new relief, the technology is likely entering stages of refined testing and potential clinical trials to determine how long the device remains effective after injection.

Future developments will likely address how the device is retrieved or if it is biodegradable. If successful, the technology could expand beyond pain relief to treat other neurological conditions where nerve modulation is required but surgery is too risky for the patient.